Stay updated with breaking news from Technology Licensee Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or...
Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products...
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in...
/PRNewswire/ -- Continues to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy; remains on track for first BLA filing in 2024...
/PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible...